Roche's Alzheimer's antibody lowers biomarkers in inherited form of disease, though impact on symptoms is unclear

When experimental anti-amyloid antibodies from Eli Lilly and Roche failed to improve symptoms of Alzheimer’s disease in a phase 2/3 study led by Washington University School of Medicine and reported last year, it raised serious doubts about the future of the medicines. But the trial continued, and, now, the study leaders say they have evidence that one of the drugs—Roche’s gantenerumab—could help a subset of patients.